---
figid: PMC11506536__cancers-16-03548-g002
figtitle: Illustrates the multifaceted mechanisms of action of niclosamide in cancer
  treatment
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11506536
filename: cancers-16-03548-g002.jpg
figlink: /pmc/articles/PMC11506536/figure/F2/
number: F2
caption: Illustrates the multifaceted mechanisms of action of niclosamide in cancer
  treatment. It depicts niclosamide as a mitochondrial uncoupler that disrupts ATP
  production and induces Cytc release, leading to apoptosis through reactive oxygen
  species (ROS) generation, and niclosamide’s inhibition of the STAT3 signaling pathway,
  blocking cancer cell proliferation; disruption of the mTOR pathway via activation
  of the tuberous sclerosis complex (TSC); degradation of LRP6 to inhibit the Wnt/β-catenin
  pathway; and suppression of the NF-κB pathway by inhibiting IκB kinase (IKK), thus
  reducing anti-apoptotic gene expression [32]. Collectively, these actions highlight
  niclosamide’s potential as a versatile therapeutic agent in oncology (Created with
  BioRender)
papertitle: 'Optimizing Niclosamide for Cancer Therapy: Improving Bioavailability
  via Structural Modification and Nanotechnology'
reftext: Russell Wiggins, et al. Cancers (Basel). 2024 Oct;16(20).
year: '2024'
doi: 10.3390/cancers16203548
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: Multidisciplinary Digital Publishing Institute  (MDPI)
keywords: niclosamide | anticancer drug | mechanism of action | bioavailability |
  drug delivery
automl_pathway: 0.9273053
figid_alias: PMC11506536__F2
figtype: Figure
redirect_from: /figures/PMC11506536__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11506536__cancers-16-03548-g002.html
  '@type': Dataset
  description: Illustrates the multifaceted mechanisms of action of niclosamide in
    cancer treatment. It depicts niclosamide as a mitochondrial uncoupler that disrupts
    ATP production and induces Cytc release, leading to apoptosis through reactive
    oxygen species (ROS) generation, and niclosamide’s inhibition of the STAT3 signaling
    pathway, blocking cancer cell proliferation; disruption of the mTOR pathway via
    activation of the tuberous sclerosis complex (TSC); degradation of LRP6 to inhibit
    the Wnt/β-catenin pathway; and suppression of the NF-κB pathway by inhibiting
    IκB kinase (IKK), thus reducing anti-apoptotic gene expression [32]. Collectively,
    these actions highlight niclosamide’s potential as a versatile therapeutic agent
    in oncology (Created with BioRender)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - RPSA
  - LRP1
  - PTPRA
  - MVP
  - NFKB1
  - TNF
  - CSNK1A1
  - NFKBIA
  - APC
  - PROC
  - GSK3B
  - CD40
  - ARHGEF7
  - ASCC1
  - H3P40
  - AXIN1
  - AXIN2
  - RELA
  - SYT1
  - GORASP1
  - WNK1
  - HNF4A
  - MTOR
  - ATP8A2
  - PRPH2
  - TST
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - STAT3
  - SLC12A3
  - TSC1
  - TESC
  - TSC2
  - AKT1
  - AKT2
  - AKT3
  - RICTOR
  - MAPKAP1
  - MLST8
  - RHEB
  - RHEBP1
  - OTP
  - OPN1MW
  - OPN1MW2
  - OPN1MW3
  - RPTOR
  - Niclosamide
  - TNF-a
  - Insulin
  - TSC
  - Raptor
---
